

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-35. (Cancelled)

36. (Currently Amended) A liposomal formulation, said liposomal formulation comprising a liposome having vinorelbine in solution free antineoplastic drug and precipitated antineoplastic drug vinorelbine, wherein the precipitated antineoplastic drug vinorelbine in said liposome is at least 50% of the total antineoplastic drug vinorelbine, wherein said liposome comprises sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol%/mol% sphingomyelin/cholesterol to about 35/30/50 mol%/mol% sphingomyelin/cholesterol, and wherein said antineoplastic drug is a vinca alkaloid and wherein the ratio of said vinoelbione to lipid is 0.1-0.5:1 (w/w).

37.-42. (Cancelled)

43. (Currently Amended) The liposomal formulation of claim 32 or 36, wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 molar ratio.

44.-65. (Cancelled)

66. (Currently Amended) The liposomal formulation of claim 65 or 36, wherein the ratio of said antineoplastic drug vinorelbine to said lipid is about 0.1-0.5:1 (w/w).

67. (Currently Amended) The liposomal formulation of claim 32 or 36, wherein said liposome comprises sphingomyelin and cholesterol in a 50:50 molar ratio.

68. (New) The liposomal formulation of claim 66, wherein the ratio of said vinorelbine to said lipid is about 0.3:1 (w/w).